Innovent doses first patient in Phase 3 China trial of IBI3003 tri-specific antibody for multiple myeloma

• Innovent dosed the first patient in a China Phase 3 trial of IBI3003, a tri-specific antibody for relapsed or refractory multiple myeloma.
• The study will compare IBI3003 with standard combination regimens, with progression-free survival as the primary endpoint.
• Early clinical results were already presented in December 2025, showing encouraging responses with manageable safety in heavily pretreated patients.
• Further dose-optimization results are expected at future medical meetings, supporting the program’s registrational strategy in China.
• The drug also holds FDA Fast Track status for later-line patients, with a separate US Phase 1/2 study ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606212000PR_NEWS_USPR_____CN88366) on June 22, 2026, and is solely responsible for the information contained therein.